The outcome of endometrial ablation in women with inherited bleeding disorders


Dr. R. A. Kadir, Department of Obstetrics and Gynaecology, Haemophilia Centre, Royal Free Hospital, London, NW3 2QG, UK.
Tel.: 0207 7940500, ext. 35317; fax: 0207 4726759;


Summary.  There are currently limited data on the use of endometrial ablation in the treatment of heavy menstrual bleeding (HMB) in women with inherited bleeding disorders (IBDs). A retrospective review of prospectively collected data was performed. Twelve women with IBDs who had received endometrial ablation for the treatment of HMB were identified and their records reviewed. Details of their menstrual history; quality of life (QOL) and amount of menstrual blood loss [as assessed by pictorial blood-loss assessment chart (PBAC) and haemoglobin (Hb) concentration] pre and post-ablation were collected. Twelve women were included. The median duration of follow-up post-ablation was 32 months (range, 6–76). The median duration of menstruation decreased from 11 to 0 days after treatment (= 0.004). Median PBAC scores decreased from 1208 preop to 0 post-ablation (= 0.002).The median Hb concentrations (10.5–13.1 g dL−1) and QOL scores (median, 17–54) improved significantly after endometrial ablation (< 0.01). Endometrial ablation appears to be a safe and effective long-term treatment for HMB in women with IDBs. It significantly decreases menstrual blood loss and improves QOL.